

## Special Issue

# Emerging Therapies for Germ Cell Tumors

### Message from the Guest Editors

Germ cell tumors (GCTs) represent the most common malignancy in young adult males and are among the most curable solid tumors, largely due to their exceptional sensitivity to cisplatin-based chemotherapy. However, a subset of patients experience relapse or develop cisplatin-resistant disease. In recent years, advances in molecular biology, immunology, and epigenetics have opened new avenues for therapeutic innovation in GCTs. This Special Issue highlights recent advancements in therapies aimed at enhancing outcomes for patients with refractory or high-risk diseases. Contributions include a variety of strategies, such as immunotherapies, epigenetic modulators, and novel biomarkers for precision oncology. The use of high-throughput genomic profiling, circulating tumor DNA (ctDNA), and microRNA for personalized treatment is also gaining attention. By combining preclinical findings and clinical trial insights, this Special Issue provides an overview of the evolving therapeutic landscape. These emerging strategies offer promise for overcoming resistance, reducing treatment-related side effects, and improving the quality of life for GCT patients.

### Guest Editors

Dr. Ratnakar Singh

Department of Comparative Biosciences, University of Illinois at Urbana-Champaign, Urbana, IL 61801, USA

Dr. Krinio Giannikou

Department of Urology, University of California San Diego, La Jolla, CA, USA

### Deadline for manuscript submissions

30 June 2026



## Cancers

an Open Access Journal  
by MDPI

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/si/245650](https://mdpi.com/si/245650)

*Cancers*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[cancers@mdpi.com](mailto:cancers@mdpi.com)

[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)





# Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)



## About the Journal

### Message from the Editor-in-Chief

*Cancers* (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

---

### Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)